Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model (DIGITAL PREV)
Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.
This study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ravenna
-
Cotignola, Ravenna, Italy, 48033
- Recruiting
- Maria Cecilia Hospital
-
Contact:
- Anna Maria Malagoni, Dr
- Phone Number: +390545217213
- Email: amalagoni@gvmnet.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 40 and 75 years
- hypertension
- hyperglycaemia
- type 2 diabetes not requiring insulin therapy
- dyslipidaemia
- active smoking
- overweight/grade I obesity
- Willingness to participate in follow-up visits over 24 months
Exclusion Criteria:
- previous myocardial infarction
- stroke
- transient ischemic attack
- coronary artery diseas
- peripheral arterial occlusive disease
- heart failure
- Type 1 or type 2 diabetes mellitus on insulin therapy
- Advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m²)
- Active cancer disease
- Severe obesity
- Inability to use digital tools
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Digital technology
Remote management of study participants, enabling the structured collection of relevant information for follow-up.
|
Recommendations to the patient
|
|
Other: on site
adherence to in-person follow-up at the hospital.
|
Recommendations to the patient
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood pressure
Time Frame: 12 months
|
Systolic and diastolic in millimeters of mercury
|
12 months
|
|
number of cigarettes
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
body weigh
Time Frame: 24 months
|
24 months
|
|
number of daily steps
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- DIGITAL PREV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular (CV) Risk
-
NCT07629518Not yet recruitingCardiovascular (CV) Risk
-
NCT07205237CompletedCardiovascular (CV) Risk
-
NCT07403305Not yet recruiting
-
NCT07147387Not yet recruitingCardiovascular (CV) Risk
-
NCT04014348Recruiting
-
NCT07605442Not yet recruitingCardiovascular (CV) Risk
-
NCT07545343Not yet recruitingSubclinical Cardiovascular Impairments | Cardiovascular (CV) Risk | MASLD
-
NCT07205692RecruitingMultimorbidity | Kidney Transplant | Cardiovascular (CV) Risk
-
NCT07067398RecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk Factors
-
NCT07166822RecruitingExercise | Cardiovascular (CV) Risk
Clinical Trials on Recommendations to the patient.
-
NCT03116607Completed
-
NCT01508819CompletedElderly Patients Visiting the Emergency Department
-
NCT05310513CompletedIntensive Care Units | Posterior Reversible Encephalopathy Syndrome
-
NCT06514833Not yet recruiting
-
NCT03140150Terminated
-
NCT07267572Not yet recruiting
-
NCT06425068CompletedSkin Abnormalities | Skin; Injury, Superficial | Skin; Ulcer, Decubitus
-
NCT06360315Active, not recruiting
-
NCT07421154Not yet recruitingHemophilia A and B